Drug Type Therapeutic vaccine, Genetically engineered subunit vaccine |
Synonyms BLS M22, BLS-M22, BLS-MX022 + [1] |
Target |
Action inhibitors |
Mechanism MSTN inhibitors(Growth/differentiation factor 8 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophy, Duchenne | Phase 1 | United States | 04 Jun 2019 |